Search results
Showing 3316 to 3330 of 9008 results
The NICE board sets out our strategic priorities and policies.
Consultation on changes to technology appraisals and highly specialised technologies
Home What NICE does Our guidance About technology appraisal guidance Our methods and processes (health technology evaluation manual) Methods and...
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios Services for older people {"@context":"http://schema.org"
Read biographies of the members of our quality standards advisory committee.
More detail about Diagnostics Advisory Committee (DAC) registration, meeting arrangements and types of attendee.
More detail about Interventional Procedures Advisory Committee (IPAC) registration, meeting arrangements and types of attendee.
More detail about Medical Technologies Advisory Committee (MTAC) registration, meeting arrangements and types of attendee.
Home Get involved Our committees NICE committee meetings...
Providing an advisory service for international health organisations, ministries and government agencies whose task is to improve evidence-based decision making in health and social care
This indicator covers the percentage of patients with diabetes, on the register, who have a record of retinal screening in the preceding 12 month. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM98.
This indicator covers the percentage of patients with diabetes, on the register, with a diagnosis of nephropathy (clinical proteinuria) or micro-albuminuria who are currently treated with an ACE-I (or ARBs). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM95.
This indicator covers the percentage of patients on the CKD register who are treated with an SGLT-2 inhibitor if they have: type 2 diabetes, or no type 2 diabetes and an eGFR 20 ml/min/1.73 m2 to 44 ml/min/1.73 m2 and are currently treated with an ACE inhibitor or angiotensin receptor blocker (ARB) (unless these are contraindicated) or an eGFR 45 ml/min/1.73 m2 to 59 ml/min/1.73 m2, are currently treated with an ACE inhibitor or ARB (unless these are contraindicated) and have a urine albumin-to-creatinine ratio (ACR) of 22.6 mg/mmol or more. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes.
The complete list of all our published indicators, for measuring outcomes that reflect the quality of care or processes, linked by evidence to improved outcomes.
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway.
NICE work with the NHS, patients and carers, healthcare professionals and organisations to help put our guidance into practice.